These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20528877)

  • 21. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
    Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
    Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.
    Müller F; Cunningham T; Liu XF; Wayne AS; Pastan I
    Clin Cancer Res; 2016 Oct; 22(19):4913-4922. PubMed ID: 27114443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.
    Müller F; Stookey S; Cunningham T; Pastan I
    Oncotarget; 2017 May; 8(19):30644-30655. PubMed ID: 28423727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.
    Ito C; Evans WE; McNinch L; Coustan-Smith E; Mahmoud H; Pui CH; Campana D
    J Clin Oncol; 1996 Aug; 14(8):2370-6. PubMed ID: 8708730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of CD22 expression in acute lymphoblastic leukemia.
    Shah NN; Stevenson MS; Yuan CM; Richards K; Delbrook C; Kreitman RJ; Pastan I; Wayne AS
    Pediatr Blood Cancer; 2015 Jun; 62(6):964-9. PubMed ID: 25728039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
    Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
    Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
    Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
    Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
    Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
    Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
    Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia.
    Maung ZT; Hogarth L; Reid MM; Proctor SJ; Hamilton PJ; Hall AG
    Leukemia; 1994 Sep; 8(9):1487-91. PubMed ID: 8090028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
    Vallera DA; Oh S; Chen H; Shu Y; Frankel AE
    Mol Cancer Ther; 2010 Jun; 9(6):1872-83. PubMed ID: 20530709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxetumomab Pasudotox: First Global Approval.
    Dhillon S
    Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
    de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
    Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.
    Wei H; Bera TK; Wayne AS; Xiang L; Colantonio S; Chertov O; Pastan I
    J Biol Chem; 2013 Apr; 288(17):12305-12. PubMed ID: 23486472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
    Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
    Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
    Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of Aplidin in acute lymphoblastic leukaemia cells.
    Erba E; Serafini M; Gaipa G; Tognon G; Marchini S; Celli N; Rotilio D; Broggini M; Jimeno J; Faircloth GT; Biondi A; D'Incalci M
    Br J Cancer; 2003 Aug; 89(4):763-73. PubMed ID: 12915891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann T; Willingham MC; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8291-5. PubMed ID: 2236041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.